Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$2.60
+7.2%
$3.53
$2.37
$7.63
$327.41M1.42738,734 shs840,786 shs
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$5.98
+5.3%
$5.81
$3.91
$13.99
$410.46M1.58816,412 shs665,085 shs
Quantum-Si incorporated stock logo
QSI
Quantum-Si
$1.95
+0.3%
$1.31
$0.61
$5.77
$354.38M2.7110.51 million shs17.67 million shs
Transcat, Inc. stock logo
TRNS
Transcat
$92.47
+1.3%
$79.84
$67.56
$147.12
$860.76M0.69107,725 shs42,111 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
0.00%-10.04%-35.81%-52.83%-59.40%
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
0.00%-6.89%-10.83%-4.70%-49.10%
Quantum-Si incorporated stock logo
QSI
Quantum-Si
0.00%+37.59%+57.72%+32.88%+19.75%
Transcat, Inc. stock logo
TRNS
Transcat
0.00%+12.49%+7.27%+10.01%-32.11%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.0682 of 5 stars
3.12.00.00.03.21.70.6
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
2.0949 of 5 stars
3.52.00.00.03.41.70.0
Quantum-Si incorporated stock logo
QSI
Quantum-Si
2.3932 of 5 stars
3.33.00.00.03.12.50.0
Transcat, Inc. stock logo
TRNS
Transcat
1.1881 of 5 stars
2.31.00.00.02.11.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.25
Hold$5.25102.31% Upside
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
3.00
Buy$25.38324.33% Upside
Quantum-Si incorporated stock logo
QSI
Quantum-Si
2.67
Moderate Buy$3.4878.66% Upside
Transcat, Inc. stock logo
TRNS
Transcat
2.50
Moderate Buy$114.0023.29% Upside

Current Analyst Ratings Breakdown

Latest QSI, TRNS, CTKB, and EYPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2025
Transcat, Inc. stock logo
TRNS
Transcat
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$106.00 ➝ $116.00
5/19/2025
Quantum-Si incorporated stock logo
QSI
Quantum-Si
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.50
5/16/2025
Quantum-Si incorporated stock logo
QSI
Quantum-Si
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/16/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.00
5/12/2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$3.50 ➝ $3.00
5/9/2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$4.00
5/8/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$33.00 ➝ $27.00
3/19/2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$6.00 ➝ $6.00
3/6/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
3/6/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
3/5/2025
Quantum-Si incorporated stock logo
QSI
Quantum-Si
National Bankshares
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$3.65
(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$197.05M1.67$0.01 per share206.16$2.90 per share0.89
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$56.04M7.34N/AN/A$5.66 per share1.06
Quantum-Si incorporated stock logo
QSI
Quantum-Si
$3.44M103.46N/AN/A$1.92 per share1.01
Transcat, Inc. stock logo
TRNS
Transcat
$278.42M3.09$3.41 per share27.14$30.19 per share3.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$12.15M-$0.09N/AN/A-5.05%-2.58%-2.05%8/5/2025 (Estimated)
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$70.79M-$2.41N/AN/AN/A-226.57%-43.01%-31.63%8/6/2025 (Estimated)
Quantum-Si incorporated stock logo
QSI
Quantum-Si
-$95.96M-$0.68N/AN/AN/A-3,968.84%-36.96%-33.57%8/6/2025 (Estimated)
Transcat, Inc. stock logo
TRNS
Transcat
$13.65M$1.5649.9835.16N/A6.22%7.23%5.67%8/4/2025 (Estimated)

Latest QSI, TRNS, CTKB, and EYPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/19/2025Q4 2025
Transcat, Inc. stock logo
TRNS
Transcat
$0.66$0.64-$0.02$0.48$76.40 million$77.13 million
5/15/2025Q1 2025
Quantum-Si incorporated stock logo
QSI
Quantum-Si
-$0.17-$0.11+$0.06-$0.11$0.96 million$0.84 million
5/8/2025Q1 2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$0.04-$0.09-$0.05-$0.09$43.18 million$41.46 million
5/7/2025Q1 2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$0.65-$0.65N/A-$0.65$8.84 million$24.50 million
3/5/2025Q4 2024
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$0.54-$0.64-$0.10-$0.64$11.02 million$11.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/AN/AN/AN/AN/A
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/AN/AN/AN/AN/A
Quantum-Si incorporated stock logo
QSI
Quantum-Si
N/AN/AN/AN/AN/A
Transcat, Inc. stock logo
TRNS
Transcat
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A
6.21
5.47
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/A
5.50
5.45
Quantum-Si incorporated stock logo
QSI
Quantum-Si
N/A
13.42
13.15
Transcat, Inc. stock logo
TRNS
Transcat
0.14
2.42
1.98

Institutional Ownership

CompanyInstitutional Ownership
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
69.46%
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
99.41%
Quantum-Si incorporated stock logo
QSI
Quantum-Si
39.90%
Transcat, Inc. stock logo
TRNS
Transcat
98.34%

Insider Ownership

CompanyInsider Ownership
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
9.60%
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
4.74%
Quantum-Si incorporated stock logo
QSI
Quantum-Si
30.04%
Transcat, Inc. stock logo
TRNS
Transcat
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
500126.66 million116.45 millionOptionable
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
12068.81 million65.02 millionOptionable
Quantum-Si incorporated stock logo
QSI
Quantum-Si
150183.14 million99.84 millionOptionable
Transcat, Inc. stock logo
TRNS
Transcat
9209.31 million9.10 millionOptionable

Recent News About These Companies

Analysts Set Transcat, Inc. (NASDAQ:TRNS) Price Target at $111.50
Q3 Earnings Estimate for Transcat Issued By Northland Capmk
What is HC Wainwright's Estimate for Transcat Q1 Earnings?
Transcat (NASDAQ:TRNS) Given Buy Rating at HC Wainwright
What is Northland Capmk's Forecast for Transcat Q1 Earnings?
What is HC Wainwright's Forecast for Transcat Q4 Earnings?
Transcat (NASDAQ:TRNS) Upgraded at Wall Street Zen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cytek Biosciences stock logo

Cytek Biosciences NASDAQ:CTKB

$2.60 +0.18 (+7.23%)
As of 02:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

EyePoint Pharmaceuticals stock logo

EyePoint Pharmaceuticals NASDAQ:EYPT

$6.00 +0.32 (+5.63%)
As of 02:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Quantum-Si stock logo

Quantum-Si NASDAQ:QSI

$1.94 +0.01 (+0.26%)
As of 02:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.

Transcat stock logo

Transcat NASDAQ:TRNS

$92.59 +1.27 (+1.39%)
As of 02:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Transcat, Inc. provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services. This segment also provides CalTrak, a proprietary document and asset management system that is used to manage the workflow of its calibration service centers and customers' assets; and Compliance, Control and Cost, an online customer portal that provides its customers with web-based asset management capability, as well as a safe and secure off-site archive of calibration and other service records. The Distribution segment sells and rents test, measurement, and control instruments for customers' test and measurement instrumentation needs, as well as value added services, such as calibration/certification of equipment purchase, equipment rental, used equipment for sale, and equipment kitting. This segment markets and sells its products through website, digital and print advertising, proactive outbound sales, and an inbound call center. The company provides services and products to highly regulated industries, principally life science, which includes companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries; and additional industries, including aerospace and defense industrial manufacturing, energy and utilities, and other industries that require accuracy in processes and confirmation of the capabilities of their equipment. Transcat, Inc. was incorporated in 1964 and is headquartered in Rochester, New York.